Why is Argen-X stock climbing today?
- Investing.com
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
argenx NV ADR (ARGX)
argenx NV ADR stock price live, this page displays NASDAQ ARGX stock exchange data. View the ARGX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the argenx NV ADR real time stock price chart below.
What Is the argenx NV ADR Stock Price Today?
The argenx NV ADR stock price today is 1,048.90.
What Is the Stock Symbol for argenx NV ADR?
The stock ticker symbol for argenx NV ADR is ARGX.
Is ARGX the Same as $ARGX?
$ARGX is a common way to refer to the argenx NV ADR ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does argenx NV ADR Trade On?
argenx NV ADR is listed and trades on the NASDAQ stock exchange.
Is argenx NV ADR a Good Stock to Buy?
Determining whether argenx NV ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current argenx NV ADR share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARGX quote. (ISIN: US04016X1019)
What Is the argenx NV ADR Stock Price Today?
The argenx NV ADR stock price today is 1,048.90.
What Is the Stock Symbol for argenx NV ADR?
The stock ticker symbol for argenx NV ADR is ARGX.
Is ARGX the Same as $ARGX?
$ARGX is a common way to refer to the argenx NV ADR ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does argenx NV ADR Trade On?
argenx NV ADR is listed and trades on the NASDAQ stock exchange.
Is argenx NV ADR a Good Stock to Buy?
Determining whether argenx NV ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current argenx NV ADR share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARGX quote. (ISIN: US04016X1019)
1,048.90
+29.41(+2.88%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1,033.30
1,051.98
52 wk Range
661.85
1,058.69
ARGX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1,033.301,051.98
52 wk Range
661.851,058.69
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ARGX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
9 analysts have revised their earnings upwards for the upcoming period
Argenx receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Why is Argen-X stock climbing today?
- Investing.com
- Argenx receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Argenx receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
argenx NV ADR SWOT Analysis
Execution Risks | Dependence on single product creates vulnerability to competitive pressures, pricing constraints, and the challenge of sustaining double-digit growth rates |
Market Expansion | International expansion and potential label extensions into additional indications position argenx to broaden its addressable patient population significantly |
Price Target Outlook | Wells Fargo and Truist Securities raised targets to $1,317 and $1,030 respectively, with average targets reflecting confidence in multi-year growth |
Vyvgart's Trajectory | Analysts project Vyvgart revenue reaching $6.5 billion with accelerating quarterly growth from Q2-Q4 2026, reflecting strengthened market penetration |
argenx NV ADR Earnings Call Summary for Q1/2026
- Argenx Q1 2026 EPS of $5.52 beat estimates of $5.45, but revenue of $1.3B missed forecast of $1.32B; shares fell 3.14% to $782.17 in pre-market.
- Revenue surged 63% YoY driven by U.S. VYVGART sales; operating margin reached 30% with operating profit jumping 183% YoY to $394M.
- Cash reserves grew $400M to $4.9B; company maintains gross margin of ~90% and holds more cash than debt, supporting strategic investments.
- Management projects Q3 2026 revenue of $1.44B and Q4 2026 revenue of $1.57B, focusing on maximizing VYVGART franchise and pipeline advancement.
- CEO Van Hauwermeiren cited strong VYVGART economics and cost discipline; CFO Woods emphasized robust cash position for long-term value creation.
Last Updated: 05/13/2026, 01:54 PM
Read Full TranscriptEarnings
Latest Release
Jul 23, 2026
EPS / Forecast
7.32 / 6.35
Revenue / Forecast
1.52B / 1.45B
Compare ARGX to Peers and Sector
Metrics to compare | ARGX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipARGXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 38.2x | 25.7x | −0.4x | |
PEG Ratio | 0.94 | 0.18 | 0.00 | |
Price / Book | 7.8x | 4.1x | 2.6x | |
Price / LTM Sales | 12.3x | 3.9x | 3.0x | |
Upside (Analyst Target) | 12.8% | 34.3% | 46.9% | |
Fair Value Upside | Unlock | 9.7% | 5.3% | Unlock |
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the argenx ADR (ARGX) Stock Price Today?
The argenx ADR stock price today is 1,048.90 USD.
What Stock Exchange Does argenx ADR Trade On?
argenx ADR is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for argenx ADR?
The stock symbol for argenx ADR is "ARGX."
What Is the argenx ADR Market Cap?
As of today, argenx ADR market cap is 65.59B USD.
What Is argenx ADR's Earnings Per Share (TTM)?
The argenx ADR EPS (TTM) is 26.21.
When Is the Next argenx ADR Earnings Date?
argenx ADR will release its next earnings report on Oct 22, 2026.
From a Technical Analysis Perspective, Is ARGX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has argenx ADR Stock Split?
argenx ADR has split 0 times.
How Many Employees Does argenx ADR Have?
argenx ADR has 1863 employees.
What is the current trading status of argenx ADR (ARGX)?
As of Aug 26, 2026, argenx ADR (ARGX) is trading at a price of 1,048.90 USD, with a previous close of 1,019.49 USD. The stock has fluctuated within a day range of 1,033.30 USD to 1,051.98 USD, while its 52-week range spans from 661.85 USD to 1,058.69 USD.
What Is the ARGX Premarket Price?
ARGX's last pre-market stock price is 1,034.62 USD. The pre-market share volume is 8,720.00, and the stock has decreased by 15.13, or 1.48%.
What Is the ARGX After Hours Price?
ARGX's last after hours stock price is 1,042.95 USD, the stock has decreased by 23.46, or 2.30%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.